orang
js
du
w
falsey
ar
therapeut
immunoglobulin
select
high
antibodi
titer
rsv
also
contain
high
antibodi
titer
respiratori
virus
specif
antibodi
infect
relev
patient
primari
immunodefici
diseas
routin
evalu
commerci
polyclon
immunoglobulin
prepar
polyclon
immunoglobulin
prepar
plasma
donor
high
neutral
antibodi
titer
respiratori
syncyti
viru
rsv
studi
presenc
antibodi
titer
seven
addit
respiratori
virus
donor
select
antibodi
titer
rsv
immunoglobulin
prepar
significantli
higher
titer
virus
compar
present
commerci
avail
therapeut
immunoglobulin
product
p
p
consid
donorspecif
attribut
random
donor
plasma
sampl
studi
individu
identifi
signific
correl
rsv
antibodi
titer
respiratori
viru
titer
donor
high
rsv
titer
like
higher
titer
respiratori
virus
find
suggest
either
humor
antivir
respons
bia
frequent
viral
exposur
certain
individu
major
primari
immunodefici
diseas
pidd
includ
defici
immunoglobulin
quantiti
andor
qualiti
left
untreat
defici
lead
increas
risk
recurr
upper
lower
respiratori
tract
infect
well
bacteri
sepsi
bacteri
sepsi
result
immedi
fatal
recurr
respiratori
infect
result
chronic
lung
diseas
bronchiectasi
fortun
infecti
suscept
pidd
along
risk
mitig
substant
degre
immunoglobulin
replac
therapi
therapeut
immunoglobulin
abl
reduc
incid
infect
pidd
larg
part
owe
divers
antibodi
specif
pathogen
contain
within
plasma
thousand
differ
healthi
donor
qualiti
therapeut
immunoglobulin
monitor
evalu
number
way
intact
antigen
recognit
igg
therapeut
immunoglobulin
product
gage
presenc
minim
titer
specif
antibodi
expect
gener
popul
refer
potenc
test
unit
state
food
drug
administr
requir
potenc
test
achiev
minim
standard
measl
diphtheria
polio
fda
cfr
pathogen
remain
relev
least
degre
especi
measl
infecti
diseas
specif
relev
pidd
patient
need
immunoglobulin
replac
commerci
avail
immunoglobulin
therefor
standard
specif
antibodi
content
common
infecti
diseas
pidd
patient
suscept
studi
titer
avail
product
report
wide
variat
much
specif
antibodi
within
given
dose
therapeut
immunoglobulin
prepar
need
provid
optim
resist
pidd
patient
remain
open
question
one
thing
clear
howev
increas
dose
standard
polyclon
immunoglobulin
associ
decreas
incid
infect
pidd
patient
respiratori
syncyti
viru
rsv
rel
ubiquit
viru
caus
infect
sever
morbid
result
high
mortal
pidd
otherwis
immunodefici
patient
present
work
investig
intraven
immunoglobulin
ivig
product
obtain
donor
hightit
antibodi
rsv
compar
commerci
avail
polyclon
therapeut
ivig
product
ivig
use
recent
complet
phase
iii
clinic
trial
pidd
patient
standard
replac
therapi
data
current
review
specif
intend
rsv
activ
trial
prevent
treat
experiment
infect
well
restor
pulmonari
histolog
normal
immun
compromis
cotton
rat
given
rsv
nasal
challeng
manuscript
prepar
sinc
gener
donor
high
antibodi
respons
rsv
question
whether
might
reflect
high
respond
rsv
also
virus
word
might
repres
either
extrem
humor
antivir
respond
select
individu
highli
expos
respiratori
virus
end
evalu
antibodi
titer
sever
common
respiratori
virus
compar
commerci
avail
ivig
prepar
deriv
donor
high
titer
respiratori
virus
investig
ivig
kindli
provid
adma
biolog
manufactur
use
cohnoncley
fraction
fda
publish
specif
intraven
immun
globulin
includ
plasma
donor
highlevel
rsv
antibodi
donor
high
titer
rsv
determin
rsv
neutral
assay
test
mna
ivig
test
releas
meet
fda
guidanc
treatment
pidd
patient
requir
donor
pool
consist
least
donor
meet
minimum
titer
measl
polio
tetanu
hepatit
b
thu
adma
biolog
inc
manufactur
achiev
standard
level
antirsv
potenc
well
meet
standard
requir
commerci
avail
polyclon
ivig
note
latter
characterist
featur
previous
avail
polyclon
rsv
hyperimmun
immunoglobulin
therefor
met
standard
measl
polio
diphtheria
titer
set
cber
refer
cber
refer
uml
respect
valu
cber
refer
cber
refer
uml
respect
three
differ
batch
investig
ivig
produc
separ
time
differ
donor
plasma
pool
differ
lot
commerci
avail
ivig
differ
manufacturesbrand
evalu
elisa
quantit
titer
influenza
b
rsv
parainfluenza
viru
serotyp
piv
human
metapneumoviru
hmpv
coronaviru
cov
coronaviru
cov
describ
elisa
assay
run
three
separ
date
blind
manner
plasma
sampl
random
donor
collect
commerci
plasma
collect
center
donor
provid
written
consent
pathogen
titer
test
plasma
donor
sampl
collect
us
fda
approv
collect
center
use
approv
standard
oper
procedur
test
method
donor
compens
donat
accord
fda
polic
donor
consent
plasma
use
variou
purpos
includ
limit
commerci
manufactur
addit
laboratori
test
reagent
etc
plasma
purifi
proteina
chromatographi
ig
fraction
bulk
recombin
proteina
sepharos
ff
resin
wash
pack
ml
conic
dilut
equal
volum
buffer
centrifug
rpm
min
supernat
remov
proteina
chromatographi
pellet
discard
sampl
supernat
transfer
proteina
column
correspond
sampl
identif
number
flow
approxim
ml
collect
graviti
flow
two
cv
ml
equilibr
buffer
pass
column
combin
flow
volum
store
bound
materi
column
remov
ml
elut
buffer
citrat
ph
collect
ml
conic
tube
contain
tri
base
bring
eluat
ph
column
centrifug
describ
collect
entir
elut
buffer
final
volum
elut
ml
recoveri
ig
calcul
base
upon
absorb
dilut
sampl
aliquot
purifi
ig
fraction
run
three
separ
time
determin
antibodi
level
use
elisa
ivig
prepar
antibodi
titer
nine
respiratori
virus
obtain
run
repeat
three
separ
occas
result
transform
log
scale
elisa
perform
detect
virusspecif
igg
nine
respiratori
virus
influenza
b
rsv
parainfluenza
viru
serotyp
piv
hmpv
coronaviru
cov
coronaviru
cov
accord
publish
method
viral
antigen
prepar
creat
infect
wholecel
lysat
virus
describ
briefli
influenza
virus
grown
mdck
cell
rsv
grown
cell
piv
virus
grown
vero
cell
frontier
immunolog
wwwfrontiersinorg
august
volum
articl
hmpv
grown
cell
coronaviru
grown
cell
coronaviru
grown
cell
cytopath
effect
extens
cell
scrape
supernat
centrifug
low
speed
pellet
resuspend
distil
steril
sonic
clarifi
cov
hmpv
purifi
discontinu
sucros
gradient
use
ultracentrifug
band
dilut
tri
nacl
edta
buffer
viral
antigen
prepar
store
use
elisa
test
ivig
perform
investig
blind
type
product
test
total
ivig
product
procur
label
product
dilut
dilut
buffer
pb
tween
edta
standard
concentr
mg
iggml
viral
antigen
prepar
dilut
previous
determin
concentr
bicarbon
buffer
coat
separ
elisa
plate
store
overnight
humidifi
chamber
follow
day
plate
wash
eight
serial
twofold
dilut
duplic
unknown
ivig
product
incub
antigenco
plate
room
temperatur
humidifi
chamber
h
initi
ivig
dilut
util
plate
wash
bound
igg
detect
alkalin
phosphataseconjug
goat
antihuman
igg
follow
substrat
known
serum
standard
includ
plate
igg
titer
specif
viru
defin
highest
dilut
optic
densiti
od
titer
data
tabul
descript
statist
differ
commerci
ivig
prepar
present
ratio
geometr
mean
rgm
along
confid
interv
rgm
p
valu
test
null
hypothesi
rgm
equal
determin
via
twosampl
twotail
student
ttest
signific
defin
p
evalu
correl
titer
rsv
titer
anoth
nonrsv
respiratori
viru
donor
level
antibodi
data
pair
match
donor
id
within
elisa
assay
replic
three
separ
repeat
referenc
run
titer
rsv
donor
pair
titer
anoth
nonrsv
viru
donor
henc
total
pair
creat
within
run
total
pair
creat
within
comparison
owe
replic
linear
correl
assess
titer
rsv
titer
anoth
nonrsv
viru
use
pearson
correl
coeffici
linear
log
scale
analysi
perform
use
sa
version
evalu
hypothesi
therapeut
polyclon
immunoglobulin
prepar
donor
plasma
high
titer
antirsv
igg
may
also
evid
increas
humor
immun
viral
pathogen
compar
aggreg
differ
lot
commerci
avail
standard
polyclon
ivig
product
case
specif
igg
rsv
antigen
evalu
elisa
well
specif
igg
antigen
prepar
eight
respiratori
virus
includ
influenza
b
hmpv
parainfluenza
viru
coronaviru
case
mean
ratio
geometr
mean
titer
commerci
polyclon
ivig
prepar
higher
figur
differ
mean
achiev
statist
signific
one
virus
hmpv
demonstr
trend
toward
signific
aggreg
mean
titer
higher
rang
higher
depend
upon
particular
viru
tabl
surprisingli
rsv
highest
lot
ivig
show
wide
rang
titer
virus
often
high
titer
one
viru
low
titer
virus
consist
lot
lot
demonstr
consist
high
titer
virus
importantli
sinc
standard
high
rsv
titer
repeat
find
high
titer
virus
across
lot
test
like
consist
featur
across
lot
prepar
manner
specif
level
antipathogen
antibodi
requir
ivig
provid
protect
mani
pathogen
infect
patient
pidd
unknown
stand
reason
greater
quantiti
antibodi
specif
pathogen
provid
greater
level
protect
number
variabl
also
need
factor
equat
actual
qualiti
affin
avid
antigenspecif
antibodi
well
inflect
point
past
increas
titer
becom
irrelev
protect
studi
exogen
appli
immunoglobulin
requir
gain
insight
question
way
translat
clinic
efficaci
howev
evid
suggest
high
pathogenspecif
antibodi
ivig
may
translat
improv
clinic
outcom
regard
particular
pathogen
demonstr
streptococcu
pneumonia
otiti
result
howev
demonstr
ivig
manufactur
plasma
pool
deriv
high
titer
antirsv
plasma
donor
contain
high
titer
antibodi
respiratori
frontier
immunolog
wwwfrontiersinorg
august
volum
articl
virus
suggest
may
direct
correl
antibodi
respond
statu
donor
rsv
respond
statu
virus
evalu
prepar
immunoglobulin
fraction
randomli
select
plasma
donor
contain
high
medium
low
titer
rsv
measur
antibodi
level
respiratori
viru
antigen
direct
correl
present
rsv
titer
nine
respiratori
virus
figur
thu
higher
rsv
titer
valu
greater
titer
nonrsv
respiratori
virus
likewis
lower
titer
rsv
correl
lower
titer
respiratori
virus
case
correl
coeffici
statist
signific
p
rang
log
scale
figur
tabl
exact
reason
contain
elev
antibodi
titer
respiratori
virus
entir
clear
reason
posit
correl
rsv
titer
virus
immunoglobulin
individu
donor
test
howev
number
possibl
consid
first
possibl
certain
individu
high
humor
immun
respond
either
gener
specif
intracellular
antigen
given
divers
mhc
concomit
linkag
mhc
allel
immun
gener
least
plausibl
specif
individu
particular
mhc
allel
higher
humor
respons
viral
vaccin
thu
donor
select
base
high
respons
rsv
may
also
high
respond
respiratori
virus
whether
donor
may
also
high
respond
pathogen
respiratori
virus
remain
studi
anoth
possibl
account
higher
respons
hightit
antibodi
rsv
donor
nonrsv
respiratori
virus
donor
may
experi
greater
divers
viral
infect
could
featur
occup
demograph
consider
routin
consid
select
plasma
donor
manufactur
therapeut
immunoglobulin
given
divers
high
antivir
titer
ivig
prepar
individu
donor
would
hypothes
former
formal
test
elit
antivir
humor
respons
howev
need
studi
establish
hypothesi
moreov
whether
find
regard
composit
hyperimmun
ivig
translat
clinic
efficaci
protect
divers
infect
howev
remain
determin
fund
studi
provid
adma
biolog
